Close

Protalix BioTherapeutics (PLX), Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. HCP
6. SPY
7. BSX
8. PI
9. NOW
10. ORCL


Go back to Protalix BioTherapeutics (PLX), Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics (PLX) Prices 7.6M Share Upsized Common Share Offering at $4.60/Sh

February 12, 2021 5:57 AM EST

Protalix BioTherapeutics, Inc. (NYSE: PLX) today announced the pricing of its previously announced underwritten public offering of 7,608,695 shares of its common stock at a public offering price of $4.60 per share. The Company granted the underwriters in the offering a 30-day option to purchase up... More